Q2 EPS Estimate for Maplight Therapeutics Cut by Analyst

Maplight Therapeutics, Inc. (NASDAQ:MPLT) – Investment analysts at HC Wainwright decreased their Q2 2026 earnings estimates for shares of Maplight Therapeutics in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.41) for the quarter, down from their previous forecast of ($1.05). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Maplight Therapeutics’ current full-year earnings is ($4.58) per share. HC Wainwright also issued estimates for Maplight Therapeutics’ Q3 2026 earnings at ($1.21) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.16) EPS, Q1 2027 earnings at ($1.36) EPS, Q2 2027 earnings at ($1.41) EPS, Q3 2027 earnings at ($1.27) EPS, Q4 2027 earnings at ($1.19) EPS and FY2027 earnings at ($5.19) EPS.

Several other research analysts also recently commented on MPLT. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Lifesci Capital raised shares of Maplight Therapeutics to a “strong-buy” rating in a report on Thursday, May 14th. TD Cowen started coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Finally, Needham & Company LLC started coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $36.89.

Maplight Therapeutics Stock Performance

MPLT opened at $29.31 on Monday. The company has a 50 day moving average of $26.24 and a 200 day moving average of $20.49. The company has a market cap of $1.25 billion and a PE ratio of -0.72. Maplight Therapeutics has a 12 month low of $12.24 and a 12 month high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.43).

Insider Activity at Maplight Therapeutics

In other news, CEO Christopher A. Kroeger sold 118,235 shares of Maplight Therapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the sale, the chief executive officer directly owned 1,394,094 shares of the company’s stock, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Erin Pennock Foff sold 4,438 shares of Maplight Therapeutics stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $28.54, for a total transaction of $126,660.52. Following the sale, the insider directly owned 346,059 shares of the company’s stock, valued at $9,876,523.86. This represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 495,244 shares of company stock valued at $14,079,461. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Maplight Therapeutics

A number of large investors have recently added to or reduced their stakes in MPLT. Blue Owl Capital Holdings LP bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $5,745,000. Seven Grand Managers LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $1,756,000. Oxford Asset Management LLP bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $312,000. Millennium Management LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $245,000. Finally, Invesco Ltd. bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $228,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.